Abarceo Pharma
  • About
  • Team
    • Management
    • Board
    • Scientific Advisors
  • Pipeline
  • News
  • Contact
Select Page

Abarceo Pharma at Investing in Life Science 2026

by SD-AbarceoPharma | Sep 28, 2026 | Diabetes, Events, Investors

https://www-static.abarceo.com/wp-content/uploads/2026/09/Biostock-2026-CEO-Adam-Bruce.mp4

Abarceo Pharma | Investing in Life Science 2026
CEO Adam Bruce presents Abarceo Pharma at Investing in Life Science 2026.

Recent Posts

  • Abarceo attends Biostock Life Science Summit
  • Abarceo attends EASD 2026 in Milan
  • Abarceo Pharma at Investing in Life Science 2026
  • Abarceo attended Biostock’s event in Stockholm
  • Abarceo attended the Almi Invest Rooftop Mingle on May 7

Recent Comments

    Abarceo Pharma AB

    Medeon Science Park
    Per Albin Hanssons vä 41, 205 12
    Malmö, Sweden

    Email: info@abarceo.com

    Abarceo Pharma is a Lund University Holding company and was founded in December 2017 by Scientific founders Prof. Claes Wollheim, MD, and Associate Prof. Albert Salehi. The company is dedicated to developing novel therapeutics for type-2 diabetes based upon a deep molecular and genetic understanding of the disease.

    ©Copyright 2018 – 2026 | All Rights Reserved | Reg. No. 559139-7160 | Privacy Policy